Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Regulatory
500 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Dabrafenib | US FDA | Melanoma | TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. | approved | May 29, 2013 | openfda |
| Dabrafenib | US FDA | Melanoma | the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. | approved | May 29, 2013 | openfda |
| Dabrafenib | US FDA | Malignant Colorectal Neoplasm | Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. | approved | May 29, 2013 | openfda |
| Dabrafenib | US FDA | Lung Non-Small Cell Carcinoma | the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. | approved | May 29, 2013 | openfda |
| Dacomitinib | US FDA | Lung Non-Small Cell Carcinoma | VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. ( 1 ) | approved | Sep 27, 2018 | openfda |
| Dacomitinib | US FDA | Lung Non-Small Cell Carcinoma | VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. ( 1 ) | approved | Sep 27, 2018 | openfda |
| Dactinomycin | US FDA | Rhabdomyosarcoma | adult and pediatric patients with rhabdomyosarcoma, as part of a multiphase, combination chemotherapy regimen. | approved | Nov 9, 2017 | openfda |
| Dactinomycin | US FDA | Ewing Sarcoma | adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. | approved | Nov 9, 2017 | openfda |
| Dactinomycin | US FDA | Malignant Testicular Neoplasm | adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. | approved | Nov 9, 2017 | openfda |
| Dactinomycin | US FDA | Wilms Tumor | adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. | approved | Nov 9, 2017 | openfda |
| Daratumumab | US FDA | Multiple Myeloma | DARZALEX is indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. DARZALEX is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. ( 1 ) | approved | Nov 16, 2015 | openfda |
| Darolutamide | US FDA | Nonmetastatic Castration-Resistant Prostate Carcinoma | NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with: non-metastatic castration-resistant prostate cancer (nmCRPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. ( 1 ) NUBEQA is indicated for the treatment of adult patients with: non-metastatic castration resistant prostate cancer (nmCRPC) metastatic castration-sensitive prostate cancer (mCSPC) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. | approved | Jul 30, 2019 | openfda |
| Datopotamab Deruxtecan | US FDA | Lung Non-Small Cell Carcinoma with EGFR Mutation | adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. | approved | Jan 17, 2025 | openfda |
| Datopotamab Deruxtecan | US FDA | Triple-Negative Breast Carcinoma | This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy [see Clinical Studies (14.2) ] .accelerated | approved | Jan 17, 2025 | openfda |
| Datopotamab Deruxtecan | US FDA | Malignant Breast Neoplasm | adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. | approved | Jan 17, 2025 | openfda |
| Degarelix | US FDA | Malignant Prostate Neoplasm | FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer. FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer. ( 1 ) | approved | Dec 24, 2008 | openfda |
| Denosumab | US FDA | Multiple Myeloma | Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. | approved | Oct 29, 2025 | openfda |
| Denosumab | US FDA | Malignant Breast Neoplasm | to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer | approved | Oct 29, 2025 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Oct 29, 2025 | openfda |
| Denosumab | US FDA | Malignant Breast Neoplasm | to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer | approved | Oct 29, 2025 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Oct 29, 2025 | openfda |
| Denosumab | US FDA | Multiple Myeloma | Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. | approved | Aug 29, 2025 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Mar 25, 2025 | openfda |
| Denosumab | US FDA | Malignant Breast Neoplasm | to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer | approved | Mar 25, 2025 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Feb 13, 2025 | openfda |
| Denosumab | US FDA | Malignant Breast Neoplasm | to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer | approved | Feb 13, 2025 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. | approved | Mar 5, 2024 | openfda |
| Denosumab | US FDA | Malignant Breast Neoplasm | to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. | approved | Mar 5, 2024 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Jun 1, 2010 | openfda |
| Denosumab | US FDA | Malignant Breast Neoplasm | to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer | approved | Jun 1, 2010 | openfda |
| Dexamethasone | US FDA | Multiple Myeloma | HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (MM). HEMADY is a corticosteroid indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma. ( 1 ) | approved | Oct 3, 2019 | openfda |
| Dexamethasone | US FDA | Conventional Osteosarcoma | The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) | approved | Jun 17, 2009 | openfda |
| Dinutuximab | US FDA | High Risk Neuroblastoma | Unituxin (dinutuximab) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy [see Clinical Studies (14) ] . Unituxin is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. ( 1 ) | approved | Mar 10, 2015 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer | approved | Oct 23, 2024 | openfda |
| Docetaxel | US FDA | Lung Non-Small Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC | approved | Oct 23, 2024 | openfda |
| Docetaxel | US FDA | Malignant Breast Neoplasm | Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC | approved | Oct 23, 2024 | openfda |
| Docetaxel | US FDA | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN | approved | Oct 23, 2024 | openfda |
| Docetaxel | US FDA | Gastric Adenocarcinoma | Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction | approved | Oct 23, 2024 | openfda |
| Docetaxel | US FDA | Gastric Adenocarcinoma | Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction | approved | Nov 22, 2022 | openfda |
| Docetaxel | US FDA | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN | approved | Nov 22, 2022 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration- Resistant Prostate Cancer (CRPC) : with prednisone in metastatic CRPC | approved | Nov 22, 2022 | openfda |
| Docetaxel | US FDA | Malignant Breast Neoplasm | Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC | approved | Nov 22, 2022 | openfda |
| Docetaxel | US FDA | Lung Non-Small Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC | approved | Nov 22, 2022 | openfda |
| Docetaxel | US FDA | Malignant Breast Neoplasm | Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC | approved | Apr 12, 2013 | openfda |
| Docetaxel | US FDA | Gastric Adenocarcinoma | Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction | approved | Apr 12, 2013 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer | approved | Apr 12, 2013 | openfda |
| Docetaxel | US FDA | Lung Non-Small Cell Carcinoma | Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC | approved | Apr 12, 2013 | openfda |
| Docetaxel | US FDA | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN | approved | Apr 12, 2013 | openfda |
| Docetaxel | US FDA | Lung Non-Small Cell Carcinoma | Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC | approved | Jun 29, 2011 | openfda |
| Docetaxel | US FDA | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN | approved | Jun 29, 2011 | openfda |
Data updated 17 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Cetuximab | 403 | 92 | 310 |
| Dasatinib | 313 | 179 | 134 |
| Imatinib | 274 | 144 | 130 |
| Erlotinib | 268 | 174 | 94 |
| Crizotinib | 262 | 141 | 121 |
| Vemurafenib | 261 | 149 | 111 |
| Gefitinib | 185 | 142 | 43 |
| Sunitinib | 164 | 91 | 72 |
| Trametinib | 157 | 129 | 28 |
| Afatinib | 129 | 120 | 9 |
| Panitumumab | 127 | 34 | 93 |
| Trastuzumab | 127 | 90 | 37 |
| Olaparib | 108 |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 105 |
| 3 |
| Dabrafenib | 107 | 74 | 33 |
| Imatinib Mesylate | 100 | 20 | 80 |
| Sorafenib | 95 | 72 | 23 |
| Bosutinib | 91 | 32 | 59 |
| Lapatinib | 85 | 64 | 21 |
| Selumetinib | 85 | 71 | 14 |
| Palbociclib | 84 | 75 | 9 |
| Larotrectinib | 79 | 63 | 16 |
| Cisplatin | 77 | 45 | 31 |
| Entrectinib | 69 | 62 | 7 |
| Ponatinib | 67 | 56 | 11 |
| Nilotinib | 65 | 20 | 45 |
| Osimertinib | 62 | 48 | 14 |
| Chemotherapy | 61 | 39 | 22 |
| Axitinib | 57 | 17 | 40 |
| Erdafitinib | 54 | 51 | 3 |
| Dactolisib | 53 | 44 | 9 |
| Pembrolizumab | 53 | 38 | 12 |
| Bevacizumab | 45 | 33 | 12 |
| Irinotecan | 44 | 12 | 32 |
| Fluorouracil | 43 | 28 | 12 |
| Gemcitabine | 43 | 29 | 13 |
| Neratinib | 43 | 40 | 3 |
| Regorafenib Anhydrous | 43 | 24 | 19 |
| Selpercatinib | 43 | 34 | 9 |
| Doxorubicin | 41 | 9 | 32 |
| Alectinib | 40 | 18 | 22 |
| Ceritinib | 40 | 27 | 13 |
| Everolimus | 39 | 34 | 4 |
| Carboplatin | 38 | 29 | 9 |
| Venetoclax | 37 | 4 | 33 |
| Fulvestrant | 35 | 30 | 5 |
| Paclitaxel | 35 | 21 | 13 |
| Vismodegib | 35 | 9 | 26 |
| Midostaurin | 33 | 28 | 4 |
| Futibatinib | 32 | 29 | 3 |
| Mercaptopurine | 31 | 2 | 28 |
| Rucaparib | 31 | 31 | 0 |
| Infigratinib | 30 | 26 | 4 |
| Sirolimus | 30 | 25 | 5 |
| Docetaxel | 29 | 20 | 9 |
| Nivolumab | 29 | 20 | 6 |
| Thioguanine | 29 | 0 | 28 |
| Lorlatinib | 28 | 21 | 7 |
| Atezolizumab | 26 | 21 | 3 |
| Pazopanib | 26 | 25 | 1 |
| Pictilisib | 26 | 25 | 1 |
| Melphalan | 25 | 1 | 24 |
| Binimetinib | 24 | 23 | 1 |
| Pertuzumab | 24 | 24 | 0 |
| Tazemetostat | 24 | 24 | 0 |
| Trastuzumab Deruxtecan | 24 | 24 | 0 |
| MDM2 Inhibitor AMGMDS3 | 23 | 1 | 22 |
| Talazoparib | 23 | 23 | 0 |
| Temozolomide | 23 | 20 | 3 |
| Capivasertib | 22 | 21 | 1 |
| Crenolanib | 22 | 21 | 1 |
| Oxaliplatin | 22 | 6 | 16 |
| Quizartinib | 22 | 13 | 8 |
| BRAF Inhibitor | 21 | 21 | 0 |
| Brigatinib | 21 | 12 | 9 |
| Gilteritinib | 21 | 18 | 3 |
| Alpelisib | 20 | 15 | 5 |
| Cobimetinib | 20 | 20 | 0 |
| Enzalutamide | 20 | 8 | 12 |
| Aspirin | 19 | 19 | 0 |
| Regorafenib | 19 | 12 | 7 |
| Tamoxifen | 19 | 11 | 8 |
| Trastuzumab Emtansine | 19 | 10 | 9 |
| Cabozantinib | 18 | 17 | 1 |
| Capecitabine | 18 | 11 | 4 |
| Capmatinib | 18 | 15 | 1 |
| Sotorasib | 18 | 17 | 0 |
| Cytarabine | 17 | 5 | 12 |
| Mitogen-Activated Protein Kinase Kinase Inhibitor | 17 | 15 | 2 |
| Pralsetinib | 17 | 11 | 6 |
| Dacomitinib | 16 | 15 | 1 |
| Immune Checkpoint Inhibitor | 16 | 13 | 2 |
| Ivosidenib | 16 | 16 | 0 |
| Lestaurtinib | 16 | 15 | 1 |
| Pemetrexed | 16 | 11 | 5 |
| PI103 | 16 | 16 | 0 |
| Temsirolimus | 16 | 15 | 1 |
| ALK Inhibitor TAE684 | 15 | 12 | 3 |
| Daunorubicin | 15 | 4 | 11 |
| Tepotinib | 15 | 15 | 0 |
| Abiraterone | 14 | 3 | 11 |
| Encorafenib | 14 | 13 | 1 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 14 | 10 | 4 |
| Methotrexate | 14 | 2 | 9 |
| Pexidartinib | 14 | 6 | 8 |
| Platinum Compound | 14 | 13 | 1 |
| Tretinoin | 14 | 8 | 6 |
| Bafetinib | 13 | 1 | 12 |
| Dovitinib | 13 | 13 | 0 |
| Ruxolitinib | 13 | 13 | 0 |
| Ibrutinib | 12 | 6 | 6 |
| Prednisone | 12 | 12 | 0 |
| Belvarafenib | 11 | 8 | 3 |
| Durvalumab | 11 | 10 | 1 |
| Mirdametinib | 11 | 9 | 2 |
| PD173074 | 11 | 10 | 1 |
| Revumenib | 11 | 4 | 7 |
| Akt Inhibitor MK2206 | 10 | 9 | 1 |
| Asparaginase | 10 | 0 | 10 |
| Etoposide | 10 | 7 | 3 |
| Fexagratinib | 10 | 9 | 1 |
| PLX4720 | 10 | 5 | 4 |
| R3Mab | 10 | 5 | 5 |
| JQ1 | 9 | 9 | 0 |
| PI3Ka/Di | 9 | 7 | 2 |
| Vandetanib | 9 | 8 | 1 |
| Inavolisib | 8 | 8 | 0 |
| Ipilimumab | 8 | 6 | 1 |
| MEK Inhibitor CI-1040 | 8 | 8 | 0 |
| Niraparib | 8 | 8 | 0 |
| Panobinostat | 8 | 7 | 1 |
| Ribociclib | 8 | 5 | 3 |
| Vorinostat | 8 | 7 | 1 |
| Azacitidine | 7 | 7 | 0 |
| Foretinib | 7 | 6 | 1 |
| GSK126 | 7 | 7 | 0 |
| Mitomycin | 7 | 6 | 1 |
| MTOR Inhibitor | 7 | 7 | 0 |
| Multikinase Inhibitor AEE788 | 7 | 5 | 2 |
| Pemigatinib | 7 | 6 | 1 |
| PI-103 | 7 | 5 | 2 |
| Repotrectinib | 7 | 7 | 0 |
| Sonidegib | 7 | 4 | 3 |
| Sunvozertinib | 7 | 7 | 0 |
| Taselisib | 7 | 6 | 1 |
| VTP-50469 | 7 | 0 | 7 |
| Arsenic Trioxide | 6 | 3 | 3 |
| AZD3463 | 6 | 1 | 5 |
| Dabrafenib/Trametinib Regimen | 6 | 6 | 0 |
| Dinaciclib | 6 | 5 | 1 |
| Ipilimumab/Nivolumab Regimen | 6 | 6 | 0 |
| Linsitinib | 6 | 6 | 0 |
| Pacritinib | 6 | 6 | 0 |
| Pan-RAF/MEK Molecular Glue NST-628 | 6 | 6 | 0 |
| Radiation Therapy | 6 | 4 | 2 |
| Sapanisertib | 6 | 6 | 0 |
| Tanespimycin | 6 | 6 | 0 |
| Trabectedin | 6 | 6 | 0 |
| Veliparib | 6 | 6 | 0 |
| Adavosertib | 5 | 5 | 0 |
| ALK Inhibitor ASP3026 | 5 | 1 | 4 |
| Amivantamab | 5 | 5 | 0 |
| Buparlisib | 5 | 5 | 0 |
| Futuximab/Modotuximab Mixture | 5 | 5 | 0 |
| Hormone Therapy | 5 | 0 | 5 |
| MEK Inhibitor RO4987655 | 5 | 1 | 4 |
| Metformin | 5 | 5 | 0 |
| MTOR Kinase Inhibitor PP242 | 5 | 4 | 1 |
| PD1 Inhibitor | 5 | 4 | 1 |
| Rociletinib | 5 | 4 | 1 |
| SU11274 | 5 | 5 | 0 |
| Abemaciclib | 4 | 4 | 0 |
| Adagrasib | 4 | 4 | 0 |
| Anti-PD1 Monoclonal Antibody | 4 | 3 | 1 |
| Anti-PD-L1 Monoclonal Antibody | 4 | 2 | 2 |
| Apitolisib | 4 | 4 | 0 |
| Arabinosylguanine | 4 | 1 | 3 |
| ARS-1620 | 4 | 3 | 0 |
| Asciminib | 4 | 4 | 0 |
| Bicalutamide | 4 | 1 | 3 |
| Decitabine | 4 | 4 | 0 |
| Dordaviprone | 4 | 4 | 0 |
| Duligotuzumab | 4 | 4 | 0 |
| Enasidenib | 4 | 4 | 0 |
| Eprenetapopt | 4 | 4 | 0 |
| Exemestane | 4 | 4 | 0 |
| FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 | 4 | 4 | 0 |
| FLT3 Tyrosine Kinase Inhibitor TTT-3002 | 4 | 4 | 0 |
| Icotinib | 4 | 3 | 1 |
| JQEZ5 | 4 | 4 | 0 |
| Lenvatinib | 4 | 3 | 1 |
| Letrozole | 4 | 3 | 1 |
| Leucovorin | 4 | 4 | 0 |
| Linifanib | 4 | 4 | 0 |
| MTOR Kinase Inhibitor AZD8055 | 4 | 2 | 2 |
| Nelarabine | 4 | 1 | 3 |
| Olutasidenib | 4 | 4 | 0 |
| Phosphatidylinositide 3-Kinase Inhibitor | 4 | 4 | 0 |
| PI3Kbeta Inhibitor AZD8186 | 4 | 4 | 0 |
| PI3K/BET Inhibitor LY294002 | 4 | 4 | 0 |
| Poziotinib | 4 | 4 | 0 |
| Refametinib | 4 | 3 | 1 |
| Rogaratinib | 4 | 4 | 0 |
| Taxane Compound | 4 | 3 | 1 |
| Uprosertib | 4 | 4 | 0 |
| Vincristine | 4 | 3 | 1 |
| Vinorelbine | 4 | 4 | 0 |
| Vistusertib | 4 | 4 | 0 |
| Vorasidenib | 4 | 4 | 0 |
| Abiraterone Acetate | 3 | 0 | 3 |
| AG1295 | 3 | 3 | 0 |
| Alisertib | 3 | 3 | 0 |
| Alvespimycin | 3 | 3 | 0 |
| Anti-CTLA-4 Monoclonal Antibody | 3 | 2 | 1 |
| Anti-VEGF Monoclonal Antibody | 3 | 2 | 1 |
| ATR Inhibitor | 3 | 3 | 0 |
| Avapritinib | 3 | 3 | 0 |
| Avelumab | 3 | 2 | 1 |
| AZD-4547 | 3 | 3 | 0 |
| Birabresib | 3 | 3 | 0 |
| Bortezomib | 3 | 3 | 0 |
| B-Raf/VEGFR-2 Inhibitor RAF265 | 3 | 3 | 0 |
| Cabazitaxel | 3 | 2 | 1 |
| Canertinib | 3 | 3 | 0 |
| CDK Inhibitor SNS-032 | 3 | 3 | 0 |
| Cisplatin/Pembrolizumab/Pemetrexed Regimen | 3 | 0 | 3 |
| Deguelin | 3 | 3 | 0 |
| Dostarlimab | 3 | 3 | 0 |
| Dual IGF-1R/InsR Inhibitor BMS-754807 | 3 | 1 | 2 |
| EAP Protocol | 3 | 3 | 0 |
| Ensartinib | 3 | 3 | 0 |
| FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | 3 | 1 | 2 |
| FOLFOX-4 Regimen | 3 | 0 | 3 |
| IGF1R Monoclonal Antibody | 3 | 3 | 0 |
| Immunotherapy | 3 | 3 | 0 |
| Ipatasertib | 3 | 3 | 0 |
| KRAS G12D Inhibitor HRS-4642 | 3 | 3 | 0 |
| KW2449 | 3 | 3 | 0 |
| Lazertinib | 3 | 3 | 0 |
| Letetresgene Autoleucel | 3 | 3 | 0 |
| Lucitanib | 3 | 3 | 0 |
| Mobocertinib | 3 | 3 | 0 |
| PD98059 | 3 | 1 | 2 |
| Perifosine | 3 | 3 | 0 |
| Prednisolone | 3 | 0 | 3 |
| R406 | 3 | 3 | 0 |
| Ramucirumab | 3 | 2 | 1 |
| RapaLink-1 | 3 | 1 | 2 |
| RDEA 119 | 3 | 3 | 0 |
| RG7112 | 3 | 2 | 1 |
| Ridaforolimus | 3 | 2 | 1 |
| Savolitinib | 3 | 2 | 1 |
| SU5614 | 3 | 0 | 3 |
| Tandutinib | 3 | 2 | 1 |
| Tegafur | 3 | 0 | 0 |
| Teprotumumab | 3 | 3 | 0 |
| Tipifarnib | 3 | 3 | 0 |
| Trastuzumab Deruxtecan | 3 | 3 | 0 |
| Tremelimumab | 3 | 3 | 0 |
| Trichostatin A | 3 | 2 | 1 |
| Zongertinib | 3 | 3 | 0 |
| 5-Fluorouracil/Salicylic Acid Topical Solution | 2 | 0 | 2 |
| 7-Ethyl-10-Hydroxycamptothecin | 2 | 2 | 0 |
| Adjuvant Chemotherapy | 2 | 2 | 0 |
| AGI-5198 | 2 | 2 | 0 |
| AGS324 | 2 | 2 | 0 |
| ALK2 Inhibitor LDN-193189 | 2 | 2 | 0 |
| Alvocidib | 2 | 2 | 0 |
| Amrubicin | 2 | 1 | 1 |
| Angiogenesis Inhibitor | 2 | 2 | 0 |
| Anti-CD33 | 2 | 2 | 0 |
| Anti-ErbB3 Monoclonal Antibody AV-203 | 2 | 2 | 0 |
| Anti-PD-1 Monoclonal Antibody MEDI0680 | 2 | 2 | 0 |
| Aromatase Inhibitor | 2 | 1 | 1 |
| Aumolertinib | 2 | 1 | 1 |
| Bazedoxifene | 2 | 1 | 1 |
| Belinostat | 2 | 0 | 0 |
| BET Inhibitor | 2 | 2 | 0 |
| Camonsertib | 2 | 2 | 0 |
| Carboplatin/Paclitaxel Regimen | 2 | 2 | 0 |
| Carboplatin/Pemetrexed Regimen | 2 | 2 | 0 |
| CDK4/6 Inhibition | 2 | 1 | 1 |
| Cediranib | 2 | 2 | 0 |
| Celecoxib | 2 | 2 | 0 |
| Checkpoint Kinase Inhibitor AZD7762 | 2 | 2 | 0 |
| Chk1 Inhibitor | 2 | 2 | 0 |
| Copanlisib | 2 | 2 | 0 |
| CTX-712 | 2 | 2 | 0 |
| Derazantinib | 2 | 2 | 0 |
| Durvalumab/Tremelimumab Regimen | 2 | 2 | 0 |
| Elimusertib | 2 | 2 | 0 |
| EPZ011989 | 2 | 2 | 0 |
| Firmonertinib | 2 | 2 | 0 |
| FLT3 Inhibitor FF-10101 Succinate | 2 | 2 | 0 |
| FOLFIRI Regimen | 2 | 2 | 0 |
| Ganetespib | 2 | 1 | 1 |
| Ganitumab | 2 | 2 | 0 |
| Hematopoietic Cell Transplantation | 2 | 2 | 0 |
| Imlunestrant Regimen | 2 | 2 | 0 |
| Irbesartan | 2 | 2 | 0 |
| Izorlisib | 2 | 2 | 0 |
| JQ-1 | 2 | 2 | 0 |
| JSI-124 | 2 | 2 | 0 |
| L19IL2 | 2 | 2 | 0 |
| Levoleucovorin | 2 | 1 | 1 |
| Lometrexol | 2 | 2 | 0 |
| Lomustine | 2 | 2 | 0 |
| Lunresertib | 2 | 2 | 0 |
| Masitinib | 2 | 1 | 1 |
| Meloxicam | 2 | 2 | 0 |
| Mocetinostat | 2 | 2 | 0 |
| Motesanib | 2 | 0 | 2 |
| Nab-paclitaxel | 2 | 1 | 1 |
| Navtemadlin | 2 | 2 | 0 |
| Nimotuzumab | 2 | 2 | 0 |
| Nirogacestat | 2 | 2 | 0 |
| NSC348884 | 2 | 2 | 0 |
| NSC84167 | 2 | 2 | 0 |
| Omacetaxine Mepesuccinate | 2 | 2 | 0 |
| Palbociclib Regimen | 2 | 2 | 0 |
| Pan-AKT Kinase Inhibitor GSK690693 | 2 | 1 | 1 |
| PD-1 Ligand Inhibitor | 2 | 1 | 1 |
| Pidnarulex | 2 | 2 | 0 |
| Prexasertib | 2 | 2 | 0 |
| Quarfloxin | 2 | 2 | 0 |
| R-CHOP Regimen | 2 | 1 | 1 |
| Rebemadlin | 2 | 1 | 1 |
| Retaspimycin Hydrochloride | 2 | 2 | 0 |
| Rezatapopt | 2 | 2 | 0 |
| RG7356 | 2 | 1 | 1 |
| Rigosertib | 2 | 0 | 2 |
| Ripretinib | 2 | 2 | 0 |
| Rovalpituzumab Tesirine | 2 | 2 | 0 |
| Sacituzumab Govitecan | 2 | 0 | 2 |
| SAIT301 | 2 | 2 | 0 |
| Salinomycin | 2 | 2 | 0 |
| Salirasib | 2 | 2 | 0 |
| Selective Estrogen Receptor Covalent Antagonist H3B-6545 | 2 | 2 | 0 |
| Selitrectinib | 2 | 2 | 0 |
| Setidegrasib | 2 | 2 | 0 |
| Sevabertinib | 2 | 2 | 0 |
| Sintilimab | 2 | 2 | 0 |
| Sotrastaurin Acetate | 2 | 2 | 0 |
| Spliceostatin A | 2 | 2 | 0 |
| Sulindac | 2 | 2 | 0 |
| Taletrectinib | 2 | 2 | 0 |
| Tarextumab | 2 | 2 | 0 |
| Therapeutic Tumor Infiltrating Lymphocytes | 2 | 1 | 1 |
| Tovorafenib | 2 | 2 | 0 |
| Triciribine | 2 | 2 | 0 |
| Tucatinib | 2 | 2 | 0 |
| Tyrosine Kinase Inhibitor | 2 | 2 | 0 |
| Tyrphostin AG 1296 | 2 | 2 | 0 |
| U0126 | 2 | 0 | 2 |
| Valproic Acid | 2 | 2 | 0 |
| Vatalanib | 2 | 2 | 0 |
| Verteporfin | 2 | 2 | 0 |
| Zenocutuzumab-zbco | 2 | 2 | 0 |
| Ziftomenib | 2 | 2 | 0 |
| Zolbetuximab | 2 | 2 | 0 |
| 2,4-pyrimidinediamine | 1 | 1 | 0 |
| 2-Deoxy-D-glucose | 1 | 1 | 0 |
| 3-Dimensional Conformal Radiation Therapy | 1 | 1 | 0 |
| 4'-(9-acridinylamino)methanesulfon-m-anisidide | 1 | 0 | 1 |
| 5-Fluoro-2-Deoxycytidine | 1 | 1 | 0 |
| 6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-(4-(methylsulfonyl)phenyl)pyridin-2-amine | 1 | 1 | 0 |
| 9F7-F11 | 1 | 1 | 0 |
| A66 | 1 | 1 | 0 |
| Abemaciclib Regimen | 1 | 1 | 0 |
| Abexinostat | 1 | 1 | 0 |
| ACLY SiRNA | 1 | 1 | 0 |
| Adebrelimab | 1 | 1 | 0 |
| Ado-trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| Afamitresgene Autoleucel | 1 | 1 | 0 |
| Afimoxifene | 1 | 0 | 1 |
| Agerafenib | 1 | 1 | 0 |
| AKTi-1/2 | 1 | 1 | 0 |
| Alemtuzumab | 1 | 1 | 0 |
| ALK/TRK Inhibitor TSR-011 | 1 | 0 | 1 |
| AMG511 | 1 | 1 | 0 |
| Aminoglutethimide | 1 | 1 | 0 |
| Amphotericin B | 1 | 1 | 0 |
| Amuvatinib | 1 | 1 | 0 |
| Anthracycline Antineoplastic Antibiotic | 1 | 0 | 1 |
| Anti-CD123 | 1 | 1 | 0 |
| Anti-EGFR Monoclonal Antibody | 1 | 0 | 1 |
| Antigen-specific Cytotoxic T-lymphocyte Therapy | 1 | 1 | 0 |
| Anti-PDL1 Therapy | 1 | 1 | 0 |
| Antisecretory Factor-enriched Egg Yolk Powder Supplement | 1 | 1 | 0 |
| Anti-TIM-3 Monoclonal Antibody | 1 | 1 | 0 |
| Anvumetostat | 1 | 1 | 0 |
| Apalutamide | 1 | 0 | 1 |
| ARQ092 | 1 | 1 | 0 |
| ARS-853 | 1 | 1 | 0 |
| AS602868 | 1 | 1 | 0 |
| Aurora A Kinase Inhibitor LY3295668 Erbumine | 1 | 1 | 0 |
| Avutometinib And Defactinib | 1 | 1 | 0 |
| AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | 1 | 1 | 0 |
| AZ12908010 | 1 | 0 | 1 |
| AZ20 | 1 | 1 | 0 |
| AZ628 | 1 | 1 | 0 |
| AZ909 | 1 | 1 | 0 |
| Azathioprine | 1 | 0 | 0 |
| AZD5438 | 1 | 1 | 0 |
| Barasertib | 1 | 1 | 0 |
| BCR-ABL Inhibitor HS-10382 | 1 | 1 | 0 |
| Befotertinib | 1 | 1 | 0 |
| Berzosertib | 1 | 1 | 0 |
| Bevacizumab/Lomustine Regimen | 1 | 1 | 0 |
| Bimiralisib | 1 | 1 | 0 |
| BMVC-8C3O | 1 | 1 | 0 |
| Bone Marrow Transplantation | 1 | 1 | 0 |
| BPTES | 1 | 1 | 0 |
| C646 | 1 | 1 | 0 |
| Camptothecin | 1 | 1 | 0 |
| Camrelizumab | 1 | 1 | 0 |
| CAN508 | 1 | 1 | 0 |
| CAPOX Regimen | 1 | 1 | 0 |
| Carboplatin OR Cisplatin | 1 | 0 | 1 |
| Carfilzomib | 1 | 1 | 0 |
| Carmustine | 1 | 1 | 0 |
| C-DIM 12 | 1 | 0 | 1 |
| Cetuximab/Encorafenib Regimen | 1 | 1 | 0 |
| Cetuximab/Irinotecan Regimen | 1 | 0 | 1 |
| CH6953755 | 1 | 1 | 0 |
| CH7233163 | 1 | 1 | 0 |
| Chemoimmunotherapy | 1 | 0 | 1 |
| Chemoradiotherapy | 1 | 0 | 1 |
| Chlorambucil | 1 | 1 | 0 |
| Chloroquine | 1 | 1 | 0 |
| CHMFL-KIT-031 | 1 | 1 | 0 |
| CHZ868 | 1 | 1 | 0 |
| Cixutumumab | 1 | 1 | 0 |
| C-Met Inhibitor | 1 | 1 | 0 |
| Conatumumab | 1 | 1 | 0 |
| CTLA-4 Inhibitor | 1 | 1 | 0 |
| Cyclophosphamide | 1 | 1 | 0 |
| Cyproterone Acetate | 1 | 0 | 1 |
| Cytoreductive Surgery | 1 | 1 | 0 |
| Dacarbazine | 1 | 1 | 0 |
| Dacomitinib | 1 | 1 | 0 |
| Daromun | 1 | 1 | 0 |
| Datopotamab Deruxtecan | 1 | 1 | 0 |
| Datopotamab Deruxtecan Regimen | 1 | 1 | 0 |
| Dexamethasone | 1 | 1 | 0 |
| Disitamab Vedotin | 1 | 1 | 0 |
| Divarasib | 1 | 1 | 0 |
| Donor Lymphocyte Infusion | 1 | 1 | 0 |
| DS-6501b | 1 | 1 | 0 |
| Durvalumab Regimen | 1 | 1 | 0 |
| DVP Regimen | 1 | 0 | 1 |
| EFTX-G12V | 1 | 1 | 0 |
| EGFR Tyrosine Kinase Inhibitor Therapy | 1 | 1 | 0 |
| Elacestrant | 1 | 1 | 0 |
| Endocrine Drug Therapy | 1 | 1 | 0 |
| Enfortumab Vedotin | 1 | 1 | 0 |
| Enzastaurin | 1 | 1 | 0 |
| Epirubicin | 1 | 1 | 0 |
| EPZ004777 | 1 | 1 | 0 |
| ERBB3 Inhibitor | 1 | 1 | 0 |
| Erdafitinib Regimen | 1 | 1 | 0 |
| Eribulin | 1 | 1 | 0 |
| Erlotinib Hydrochloride | 1 | 1 | 0 |
| Everolimus/Exemestane Regimen | 1 | 1 | 0 |
| EZH2 Inhibitor | 1 | 1 | 0 |
| FAC Regimen | 1 | 0 | 1 |
| FACT Complex-targeting Curaxin CBL0137 | 1 | 1 | 0 |
| Fadraciclib | 1 | 1 | 0 |
| Fasudil | 1 | 1 | 0 |
| FEC Regimen | 1 | 0 | 1 |
| Fedratinib | 1 | 1 | 0 |
| FGFR4 Inhibitor H3B-6527 | 1 | 1 | 0 |
| FGFR Inhibitor ASP5878 | 1 | 1 | 0 |
| Fisogatinib | 1 | 1 | 0 |
| Fludarabine | 1 | 1 | 0 |
| Flutamide | 1 | 0 | 1 |
| FOLFIRI-Panitumumab Regimen | 1 | 0 | 1 |
| FOLFOX-6 Regimen | 1 | 1 | 0 |
| FOLFOX Regimen | 1 | 1 | 0 |
| G007-LK | 1 | 1 | 0 |
| G-573 | 1 | 1 | 0 |
| Galeterone | 1 | 1 | 0 |
| Galiximab | 1 | 1 | 0 |
| GDC-0879 | 1 | 1 | 0 |
| Gemtuzumab Ozogamicin | 1 | 1 | 0 |
| GF109203X | 1 | 1 | 0 |
| GNE-617 | 1 | 1 | 0 |
| Go6983 | 1 | 1 | 0 |
| GPI-15427 | 1 | 1 | 0 |
| G-Quadruplex Stabilizer BMVC | 1 | 1 | 0 |
| GSK321 | 1 | 1 | 0 |
| Guadecitabine | 1 | 1 | 0 |
| GW-2580 | 1 | 1 | 0 |
| HCI-2509 | 1 | 1 | 0 |
| HDAC Inhibitor OBP-801 | 1 | 1 | 0 |
| HDAC Inhibitor REC-2282 | 1 | 1 | 0 |
| HDM2 Inhibitor MK-8242 | 1 | 1 | 0 |
| HER2 Inhibitor CP-724,714 | 1 | 0 | 1 |
| Hydroxychloroquine | 1 | 1 | 0 |
| HyperCVAD Regimen | 1 | 1 | 0 |
| Hyperthermic Intraperitoneal Chemotherapy | 1 | 1 | 0 |
| I-BET151 | 1 | 1 | 0 |
| Ibuprofen | 1 | 1 | 0 |
| ICX-101 | 1 | 1 | 0 |
| Idarubicin | 1 | 1 | 0 |
| Idelalisib | 1 | 1 | 0 |
| IMG-2005-5 | 1 | 1 | 0 |
| Immunomodulatory Oligonucleotide | 1 | 1 | 0 |
| Inhibitor | 1 | 1 | 0 |
| Iniparib | 1 | 1 | 0 |
| Interventional Radiology Procedure | 1 | 1 | 0 |
| Iodine I-131 | 1 | 0 | 1 |
| Ionizing Radiotherapy | 1 | 0 | 1 |
| IRAK-1/4 Inhibitor | 1 | 1 | 0 |
| Ixazomib | 1 | 0 | 1 |
| JAK2 Inhibitor AZD1480 | 1 | 1 | 0 |
| JAK Inhibitor I | 1 | 1 | 0 |
| JNJ38877605 | 1 | 0 | 1 |
| JQ1 Compound | 1 | 1 | 0 |
| JW55 | 1 | 1 | 0 |
| K 252a | 1 | 0 | 1 |
| KG5 | 1 | 0 | 1 |
| KU-0060648 | 1 | 1 | 0 |
| Larotrectinib Regimen | 1 | 1 | 0 |
| Lasofoxifene | 1 | 1 | 0 |
| Lenalidomide | 1 | 0 | 1 |
| Leuprolide | 1 | 1 | 0 |
| Lifirafenib | 1 | 1 | 0 |
| Lonafarnib | 1 | 0 | 1 |
| Luminespib | 1 | 0 | 1 |
| Lumretuzumab | 1 | 1 | 0 |
| Lysine | 1 | 0 | 1 |
| MAP855 | 1 | 1 | 0 |
| Margetuximab | 1 | 1 | 0 |
| Mcl-1 Inhibitor MIK665 | 1 | 1 | 0 |
| MEK-1/MEKK-1 Inhibitor E6201 | 1 | 1 | 0 |
| MEK Inhibitor GDC-0623 | 1 | 1 | 0 |
| MEK Inhibitor REC-4881 | 1 | 1 | 0 |
| Menin Inhibitor | 1 | 1 | 0 |
| MET Tyrosine Kinase Inhibitor SGX523 | 1 | 1 | 0 |
| Molibresib | 1 | 1 | 0 |
| Monomethyl Auristatin E | 1 | 0 | 1 |
| MUC1-targeted Peptide GO-203-2C | 1 | 0 | 1 |
| Multi-subtype Natural Human Leukocyte Interferon Alpha | 1 | 0 | 1 |
| MVT Regimen | 1 | 0 | 1 |
| Nano TACs | 1 | 1 | 0 |
| Naquotinib | 1 | 0 | 1 |
| NCT00137111 | 1 | 1 | 0 |
| Nedaplatin | 1 | 0 | 1 |
| Niacinamide | 1 | 0 | 1 |
| Nilutamide | 1 | 0 | 1 |
| Ningetinib | 1 | 1 | 0 |
| Nintedanib | 1 | 1 | 0 |
| Not Applicable | 1 | 0 | 0 |
| NOTCH1 Antibody (PF-06293622) | 1 | 1 | 0 |
| NU7441 | 1 | 1 | 0 |
| Nutlin-3 | 1 | 1 | 0 |
| NVP-AEW541 | 1 | 1 | 0 |
| NVP-AST487 | 1 | 1 | 0 |
| O6-Benzylguanine | 1 | 1 | 0 |
| OICR-9429 | 1 | 1 | 0 |
| Omipalisib | 1 | 1 | 0 |
| Onalespib | 1 | 1 | 0 |
| Onartuzumab | 1 | 1 | 0 |
| Onatasertib | 1 | 1 | 0 |
| Osimertinib Mesylate | 1 | 1 | 0 |
| Paclitaxel Liposome | 1 | 1 | 0 |
| Palliative Radiation Therapy | 1 | 0 | 1 |
| Panitumumab Regimen | 1 | 1 | 0 |
| Pan-Mutant-IDH1 Inhibitor Bay-1436032 | 1 | 1 | 0 |
| Pan-RAF Inhibitor LY3009120 | 1 | 1 | 0 |
| PARP Inhibitor ABT-888 | 1 | 1 | 0 |
| PARP Inhibitor AZD2461 | 1 | 1 | 0 |
| Pasireotide | 1 | 1 | 0 |
| Patidegib | 1 | 1 | 0 |
| Patritumab | 1 | 1 | 0 |
| Patritumab Deruxtecan | 1 | 1 | 0 |
| PCV Regimen | 1 | 1 | 0 |
| PD-180970 | 1 | 1 | 0 |
| PD-L1 Inhibitor | 1 | 1 | 0 |
| Pegargiminase | 1 | 1 | 0 |
| Peginterferon Alfa-2a | 1 | 1 | 0 |
| Peginterferon Alfa-2b | 1 | 1 | 0 |
| Pembrolizumab/Pemetrexed Regimen | 1 | 1 | 0 |
| Pemrametostat | 1 | 1 | 0 |
| Pertuzumab/Trastuzumab Regimen | 1 | 0 | 1 |
| PHA-665752 | 1 | 0 | 1 |
| Picoplatin | 1 | 0 | 1 |
| Pictilisib Bismesylate | 1 | 1 | 0 |
| Pilaralisib | 1 | 1 | 0 |
| Pixantrone | 1 | 0 | 1 |
| Platinum Doublet | 1 | 0 | 1 |
| Pomalidomide | 1 | 0 | 1 |
| Porcupine Inhibitor WNT974 | 1 | 1 | 0 |
| PSI | 1 | 1 | 0 |
| Pyridostatin | 1 | 1 | 0 |
| Pyrimidine Antagonist | 1 | 1 | 0 |
| Pyrotinib | 1 | 1 | 0 |
| Quisinostat | 1 | 1 | 0 |
| Radioactive Iodine | 1 | 1 | 0 |
| Raltitrexed | 1 | 0 | 1 |
| RG5 | 1 | 0 | 1 |
| Rilotumumab | 1 | 1 | 0 |
| Rindopepimut | 1 | 1 | 0 |
| RMC-4550 | 1 | 1 | 0 |
| Roflumilast | 1 | 1 | 0 |
| Safusidenib | 1 | 1 | 0 |
| Samotolisib | 1 | 1 | 0 |
| SB202190 | 1 | 1 | 0 |
| SCH772984 | 1 | 1 | 0 |
| Selinexor | 1 | 0 | 1 |
| Seribantumab | 1 | 1 | 0 |
| Sertraline | 1 | 1 | 0 |
| SGK1-Inh | 1 | 1 | 0 |
| SHP2 Inhibitor | 1 | 1 | 0 |
| Sorafenib Tosylate | 1 | 1 | 0 |
| Stattic | 1 | 1 | 0 |
| Staurosporine | 1 | 1 | 0 |
| TAK-788 | 1 | 1 | 0 |
| Tamibarotene | 1 | 0 | 1 |
| Tarloxotinib | 1 | 1 | 0 |
| Taxol | 1 | 0 | 1 |
| Telmisartan | 1 | 1 | 0 |
| Tgx 221 | 1 | 1 | 0 |
| TGX221 | 1 | 1 | 0 |
| Therapeutic Glucocorticoid | 1 | 0 | 1 |
| Tirbanibulin | 1 | 1 | 0 |
| Tisagenlecleucel | 1 | 0 | 1 |
| Tislelizumab | 1 | 1 | 0 |
| Tizaterkib | 1 | 1 | 0 |
| Tofacitinib | 1 | 1 | 0 |
| Topotecan | 1 | 1 | 0 |
| Toripalimab | 1 | 1 | 0 |
| Tozasertib | 1 | 1 | 0 |
| Tranilast | 1 | 1 | 0 |
| Trastuzumab Deruxtecan Regimen | 1 | 1 | 0 |
| Trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| TRK Inhibitor | 1 | 1 | 0 |
| Tunlametinib | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor SU5402 | 1 | 1 | 0 |
| Tyrphostin AG 1295 | 1 | 1 | 0 |
| Tyrphostin AG 1478 | 1 | 1 | 0 |
| UNC1062 | 1 | 1 | 0 |
| UNC1999 | 1 | 1 | 0 |
| UO126 | 1 | 1 | 0 |
| VE-821 | 1 | 1 | 0 |
| VEGF/VEGFR Inhibitors | 1 | 1 | 0 |
| Vociprotafib | 1 | 0 | 0 |
| Volasertib | 1 | 1 | 0 |
| VTP50469 | 1 | 1 | 0 |
| VTX-11e | 1 | 1 | 0 |
| WHI-P154 | 1 | 1 | 0 |
| WRN Inhibitor HRO761 | 1 | 1 | 0 |
| WRN Inhibitor RO7589831 | 1 | 1 | 0 |
| WYE354 | 1 | 0 | 1 |
| WZ4002 | 1 | 0 | 1 |
| Zoledronic Acid | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.